Skip to content

Fat Loss & Metabolic Health

What Is SLU-PP-332? The Pan-ERR Agonist “Exercise Mimetic” Explained

SLU-PP-332 is not a peptide. It is a small synthetic organic molecule — a pan-agonist of the three estrogen-related receptors (ERRα, ERRβ,…

Do GLP-1 Peptides Cause Muscle Loss? Lean Mass in Weight-Loss Research

Short answer: yes — in the major weight-loss trials, a meaningful portion of the weight lost on GLP-1 receptor agonists is fat-free…

What Is Amylin? The Satiety Hormone Behind Cagrilintide Research

Amylin is a 37-amino-acid peptide hormone that pancreatic beta cells release into the bloodstream alongside insulin every time you eat. Its main…

Cagrilintide vs Semaglutide: What the Evidence Actually Shows

Search the weight-management and peptide forums for “Cagrilintide vs Semaglutide” and you will find the two treated as competing injectables — one…

CagriSema vs Tirzepatide: What the Research Actually Shows

Search the weight-management and metabolic-research forums for “CagriSema vs Tirzepatide” and you will find them ranked against each other like two entries…

AOD-9604 vs Semaglutide: Research Compared

Search the fat-loss and peptide forums for “AOD-9604 vs Semaglutide” and you will find them lined up as if they were two…

Cagrilintide vs Tirzepatide (2026): Mechanism, Evidence and Approval Status

Short answer: they are not two versions of the same drug. Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist and is FDA-approved;…

AOD-9604 vs Tesamorelin for Fat Loss

Line up AOD-9604 and tesamorelin as “fat-loss peptides” and it looks like a matchup between two comparable compounds. It is not. One…

Cagrilintide vs Retatrutide: Doses, Results and Stacking, Compared

Cagrilintide and retatrutide are different kinds of molecule with different evidence behind them, and neither is approved anywhere. Cagrilintide is a long-acting…

Tesamorelin vs CJC-1295: Doses, Evidence and Which One Has Real Data

Search for tesamorelin vs CJC-1295 and you will find the two compounds discussed side by side as if they were interchangeable options…